Abstract:Background: Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear. Methods: We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracycline, taxane, or both) to receive standard postsurgical treatment either with capecitabine or without (control). The primary end point was disease-free survival. Secondary end points included overall survival. Results: The result of the prespecified interim analysis met the primary end point, so this trial was terminated early. The final analysis showed that disease-free survival was longer in the capecitabine group than in the control group (74.1% vs. 67.6% of the patients were alive and free from recurrence or second cancer at 5 years; hazard ratio for recurrence, second cancer, or death, 0.70; 95% confidence interval [CI], 0.53 to 0.92; P=0.01). Overall survival was longer in the capecitabine group than in the control group (89.2% vs. 83.6% of the patients were alive at 5 years; hazard ratio for death, 0.59; 95% CI, 0.39 to 0.90; P=0.01). Among patients with triple-negative disease, the rate of disease-free survival was 69.8% in the capecitabine group versus 56.1% in the control group (hazard ratio for recurrence, second cancer, or death, 0.58; 95% CI, 0.39 to 0.87), and the overall survival rate was 78.8% versus 70.3% (hazard ratio for death, 0.52; 95% CI, 0.30 to 0.90). The hand-foot syndrome, the most common adverse reaction to capecitabine, occurred in 73.4% of the patients in the capecitabine group. Conclusions: After standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing. (Funded by the Advanced Clinical Research Organization and the Japan Breast Cancer Research Group; CREATE-X UMIN Clinical Trials Registry number, UMIN000000843 .).

The Effect of Capecitabine Containing Regimens on 70 Cases of Recurrent Metastatic Breast Cancer

Meta-Analysis Of Capecitabine-Based Chemotherapy Versus Capecitabine-Free Chemotherapy In Patients With Metastatic Breast Cancer

Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer

A Phase Ii, Open-Label, Multicenter, Prospective Study of Paclitaxel Plus Capecitabine with Subsequent Capecitabine Maintenance Therapy As First-Line Treatment for Metastatic or Recurrent Gastric Cancer

Evaluation of Efficacy and Toxicity of Gemcitabine in Combination with Vinorelbine in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines and Taxanes

Clinical observation of capecitabine maintenance therapy after response to capecitabine -based combination chemotherapy in patients with metastatic breast cancer

Clinical value of gemcitabine plus cisplatin or capecitabine in the treatment of resistant advanced breast cancer

144O Comparison of Efficacy and Safety of Paclitaxel and Capecitabine Followed by Capecitabine As Maintenance Therapy Versus Cisplatin and Capecitabine Therapy for Advanced Gastric Cancer: a Multicentre, Randomised, Active-Controlled Phase III Study

Long-term Survival of an Elderly Female with Metastatic Colon Cancer after Treated with Capecitabine Monotherapy

First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer: A Meta-Analysis

[Randomized Clinical Case-Control Trial for the Comparison of Docetaxel Plus Thiotepa Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer].

Capecitabine Maintenance Therapy for XT Chemotherapy-Sensitive Patients with Metastatic Triple-Negative Breast Cancer.

The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis

Short-term Curative Effects of Docetaxel Combined with Capecitabine in Neoadjuvant Chemotherapy of Triple-negative Breast Cancer and Non Triple-negative Brest Cancer

[Adjuvant Capecitabine for Residual Disease after Standard Neoadjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer]

Clinical observation of paclitaxel liposome combined with capecitabine in the treatment of advanced gastric cancer

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer

Cbcsg-10: Adjuvant Capecitabine in Combination with Docetaxel and Cyclophosphamide Plus Epirubicin for Triple Negative Breast Cancer.